Oxford Expression Technologies and Eden Biodesign Sign Co-marketing Agreement

04-Feb-2009 - Oxford Expression Technologies (OET) and Eden Biodesign have announced that they have signed a co-marketing agreement. Under the terms of the agreement, OET will offer its customers access to Eden Biodesign’s process development, clinical trial cGMP manufacturing and analytical development ...

Eden Biodesign restructures its executive management team

Dr Derek Ellison appointed Chief Operating Officer as business operations expand

30-Jan-2009 - Eden Biodesign announced a management restructure to include the appointment of Dr Derek Ellison as Chief Operating Officer (COO). The restructure results in changes in responsibility for seven executive and senior management members, to support growing demand as Eden continues to expand ...

Eden Biodesign appoints new director to spearhead drive into US project management

Maria Lusk appointed Director, Client Management as new US office opens

22-Jan-2009 - Eden Biodesign announced the appointment of Maria Lusk as Director of Client Management at its US subsidiary, Eden Biodesign, Inc. Maria’s appointment marks the formal establishment of the company’s US project management function, and coincides with the expansion of the US office, as Eden ...

Eden Biodesign signs marketing services agreement with human genome sciences

New alliance will increase Human Genome Sciences' global marketing reach for large scale cGMP manufacturing services and provides a seamless range of services for clients from process development to 20,000L scale production

15-Aug-2008 - Eden Biodesign Ltd. announced that they have entered into a marketing services agreement with Human Genome Sciences, Inc. Under the terms of the agreement, Eden Biodesign will use its expertise and global presence in the biopharmaceutical contract manufacturing market to assist HGS in identifying ...

Eden Biodesign expands Research Triangle Park Facility

19-Jun-2008 - Eden Biodesign Ltd. confirmed its expansion plans for Eden Biodesign, Inc., the Group's US subsidiary, with the announcement of a facility in the Research Triangle Park, North Carolina. Eden Biodesign, Inc., will offer a range of cell line/strain development and early process development ...

Eden Biodesign advances toward establishing its U.S. operation

Michael Faughnan appointed as Business Development Director

10-Jun-2008 - Eden Biodesign announced the appointment of Michael Faughnan as Business Development Director of its US subsidiary, Eden Biodesign, Inc. Michael will be supporting Dr. Roger Lias, President of Eden Biodesign, Inc. and Group Commercial Director, with the Company's expansion in the US and is ...

Eden Biodesign and Stealthyx Therapeutics sign deal to develop enhanced treatment for rheumatoid arthritis

10-Mar-2008 - Eden Biodesign Ltd and Stealthyx Therapeutics Ltd, a London based biotechnology company, announced that they have entered into an agreement to develop and produce Stealthyx's lead therapeutic candidate that the company is evaluating for treatment of a range of inflammatory diseases including ...

Eden Biodesign and iQur sign deal to develop a combined vaccine for the treatment of hepatitis A and B

05-Feb-2008 - Eden Biodesign Ltd and iQur Ltd, a speciality pharma company at the forefront of research to combat liver disease, announced that they have entered into an agreement to develop iQur's 'tandem core' vaccine for hepatitis A and B. Eden Biodesign will develop a unique bio-manufacturing process to ...

ImmunoBiology extends its collaboration with Eden Biodesign to develop a new generation vaccine for influenza

14-Nov-2007 - Eden Biodesign Ltd and ImmunoBiology Ltd (ImmBio) have elected to extend their initial collaboration to develop ImmBio's innovative influenza vaccine. The new contract covers a range of development and cGMP manufacturing services to produce material for ImmBio's Phase I clinical trial. Influenza ...

Eden Biodesign appoints Roger Lias as president Eden Biodesign, USA

07-Nov-2007 - Eden Biodesign Ltd announced the appointment of Dr Roger Lias as President Eden Biodesign, USA. Roger has extensive experience in the biotechnology industry with a specific emphasis on biomanufacturing services. Roger's responsibilities will include identifying and establishing strategic business ...